Filtered By:
Cancer: Sarcomas
Drug: Eloxatin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases —a phase II study
ConclusionsPanitumumab and FOLFIRI as perioperative therapy for resectable CLM result in a radiological objective response rate in 65.7% of patients with a manageable grade 3 diarrhea rate of 14.3%. Median PFS was 13.2 months, and the 24-month OS rate was 73.3%. These data are insufficient to widen the indication of panitumumab from the unresectable setting to the setting of resectable CLM.
Source: Frontiers in Oncology - August 9, 2023 Category: Cancer & Oncology Source Type: research
